- Oops!Something went wrong.Please try again later.
Shares of ChromaDex (NASDAQ:CDXC) fell in after-market trading after the company reported Q4 results.
Earnings per share were up 9.09% over the past year to ($0.10), which missed the estimate of ($0.09).
Revenue of $15,445,000 rose by 18.00% year over year, which beat the estimate of $15,360,000.
ChromaDex Sees FY21 Sales Growth 'Steady' In Ecommerce Unit, Gross Margin Improvement To Be Slightly Better Than 60%
Conference Call Details
Date: Mar 10, 2021
Time: 04:30 PM
ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fwww.google.com%2F&eventid=2947506&sessionid=1&key=BA28949A5DD50002B91BA32E315B1CC9®Tag=&V2=false&sourcepage=register
Company's 52-week high was at $23.66
Company's 52-week low was at $2.50
Price action over last quarter: Up 127.37%
ChromaDex Corp is a bioscience company dedicated to healthy aging. The ChromaDex team is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex's patent portfolio. It delivers Niagen as the sole active ingredient in its consumer product namely, Tru Niagen which is available on Tru Niagen's website and through partnerships with retailers and distributors.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.